Hormonal therapy: Historical perspective to future directionsMCLEOD, David G.Urology (Ridgewood, NJ). 2003, Vol 61, Num 2A, pp 3-7, issn 0090-4295, 5 p.Article

Hormonal Therapy for Prostate Cancer: Controversies and AdvancesMCLEOD, David G; SARTOR, Oliver.Urology (Ridgewood, NJ). 2003, Vol 61, Num 2A, issn 0090-4295, 40 p.Serial Issue

Gynecomastia in patients with prostate cancer: A review of treatment optionsMCLEOD, David G; IVERSEN, Peter.Urology (Ridgewood, NJ). 2000, Vol 56, Num 5, pp 713-720, issn 0090-4295Article

Early versus late hormonal therapy: Debating the issuesCRAWFORD, E. David.Urology (Ridgewood, NJ). 2003, Vol 61, Num 2A, pp 8-13, issn 0090-4295, 6 p.Article

Side effects of androgen deprivation therapy: Monitoring and minimizing toxicityHIGANO, Celestia S.Urology (Ridgewood, NJ). 2003, Vol 61, Num 2A, pp 32-38, issn 0090-4295, 7 p.Article

Eligard: Leuprolide acetate in a novel sustained-release delivery systemSARTOR, Oliver.Urology (Ridgewood, NJ). 2003, Vol 61, Num 2A, pp 25-31, issn 0090-4295, 7 p.Article

Sarcoidosis of the prostateFURUSATO, Bungo; KOFF, Stacey; MCLEOD, David G et al.Journal of clinical pathology. 2007, Vol 60, Num 3, pp 325-326, issn 0021-9746, 2 p.Article

Advances made in the treatment of testicular cancer in the U.S. Military: 1946 to the present : Innovations in Urology From Military MedicineHAWKSWORTH, Dorota J; MCLEOD, David G; BRASSELL, Stephen A et al.Urologic oncology. 2009, Vol 27, Num 5, pp 553-557, issn 1078-1439, 5 p.Article

Colorectal, Prostate, and Skin Cancer Screening Among Hispanic and White Non-Hispanic Men, 2000-2005JING ZHOU; ENEWOLD, Lindsey; PEOPLES, George E et al.Journal of the National Medical Association. 2011, Vol 103, Num 4, pp 343-350, issn 0027-9684, 8 p.Article

Prostate Cancer Risk Allele Specific for African Descent Associates with Pathologic Stage at ProstatectomyWHITMAN, Eric J; POMERANTZ, Mark; MCLEOD, David G et al.Cancer epidemiology, biomarkers & prevention. 2010, Vol 19, Num 1, pp 1-8, issn 1055-9965, 8 p.Article

Evaluation of the 8q24 Prostate Cancer Risk Locus and MYC ExpressionPOMERANTZ, Mark M; BECKWITH, Christine A; STAMPFER, Meir J et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 13, pp 5568-5574, issn 0008-5472, 7 p.Article

Higher Expression of the Androgen-Regulated Gene PSA/HK3 mRNA in Prostate CancerTissues Predicts Biochemical Recurrence-Free SurvivalSTERBIS, Joseph R; CHUNLING GAO; SESTERHENN, Isabell A et al.Clinical cancer research. 2008, Vol 14, Num 3, pp 758-763, issn 1078-0432, 6 p.Article

EARLY VERSUS DELAYED HORMONAL THERAPY FOR PROSTATE SPECIFIC ANTIGEN ONLY RECURRENCE OF PROSTATE CANCER AFTER RADICAL PROSTATECTOMY. CommentaryMOUL, Judd W; HONGYU WU; CHUNG, Andrew et al.The Journal of urology. 2008, Vol 179, Num 5, issn 0022-5347, S53-S60, SUPArticle

Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancerPUNGLIA, Rinaa S; CULLEN, Jennifer; MCLEOD, David G et al.Cancer. 2007, Vol 110, Num 9, pp 1973-1978, issn 0008-543X, 6 p.Article

Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortalityD'AMICO, Anthony V; MCLEOD, David G; CARROLL, Peter R et al.Cancer. 2007, Vol 109, Num 7, pp 1290-1295, issn 0008-543X, 6 p.Article

Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) early prostate cancer programIVERSEN, Peter; WIRTH, Manfred P; DELAERE, Karl P. J et al.Urology (Ridgewood, NJ). 2004, Vol 63, Num 5, pp 928-933, issn 0090-4295, 6 p.Article

The COMPARE Registry: Design and Baseline Patterns of Care for Men With Biochemical Failure After Definitive Treatment of Localized Prostate CancerSARTOR, Oliver; MCLEOD, David G; HALABI, Susan et al.Urology (Ridgewood, NJ). 2010, Vol 75, Num 3, pp 623-629, issn 0090-4295, 7 p.Article

Clinicopathological Behavior of Single Focus Prostate AdenocarcinomaRICE, Kevin R; FURUSATO, Bungo; YONGMEI CHEN et al.The Journal of urology. 2009, Vol 182, Num 6, pp 2689-2694, issn 0022-5347, 6 p., 1Article

New Treatment Approaches for Prostate Cancer Based on Peptide Analogues. CommentariesSTANGELBERGER, Anton; SCHALLY, Andrew V; DJAVAN, Bob et al.European urology. 2008, Vol 53, Num 5, pp 890-900, issn 0302-2838, 11 p.Article

Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortalityEFSTATHIOU, Jason A; CHEN, Ming-Hui; CATALONA, William J et al.Urology (Ridgewood, NJ). 2006, Vol 68, Num 2, pp 342-347, issn 0090-4295, 6 p.Article

The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomyTAYLOR, John A; KOFF, Stacey G; DAUSER, Deborah A et al.BJU international (Papier). 2006, Vol 98, Num 3, pp 540-543, issn 1464-4096, 4 p.Article

Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancerTSAI, Henry K; CHEN, Ming-Hui; MCLEOD, David G et al.Cancer. 2006, Vol 107, Num 11, pp 2597-2603, issn 0008-543X, 7 p.Article

Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancerWOLL, Michael M; HUEMAN, Matthew T; RYAN, Gayle B et al.International journal of oncology. 2004, Vol 25, Num 6, pp 1769-1780, issn 1019-6439, 12 p.Article

National comprehensive cancer network guidelines for the management of prostate cancerSCHERR, Douglas; SWINDLE, Peter W; SCARDINO, Peter T et al.Urology (Ridgewood, NJ). 2003, Vol 61, Num 2A, pp 14-24, issn 0090-4295, 11 p.Article

Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 yearsIVERSEN, Peter; MCLEOD, David G; SEE, William A et al.BJU international (Papier). 2010, Vol 105, Num 8, pp 1074-1081, issn 1464-4096, 8 p.Article